Abstract: As an emerging immunotherapy modality, chimeric antigen receptor (CAR)⁃natural killer (NK) cell therapy demonstrates significant potential in tumor treatment, achieving a pivotal breakthrough from foundational research to clinical application, particularly in the treatment of abdominal malignancies. This article provides an overview of CAR⁃NK cell therapy and systematically summarizes the research progress in its application to abdominal tumors, including hepatocellular carcinoma (HCC), gastric cancer, colorectal cancer, and pancreatic cancer. It also explores the potential of key receptors including HER2, MSLN, CEA, and EGFR in developing novel CAR⁃NK therapies. This aims to explore new treatment pathways for patients with abdominal tumors, improve their clinical prognosis, and promote the field of molecular oncology towards precision diagnosis and treatment.

Key words: Hepatocellular carcinoma')">Hepatocellular carcinoma, Gastric cancer, Colorectal cancer, Pancreatic cancer, CAR?NK cell therapy, Abdominal tumors, Precision medicine